Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 567

1.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

2.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

3.

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.

Henrickson M, Reiff A.

J Rheumatol. 2004 Oct;31(10):2055-61.

PMID:
15468375
4.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

5.

Etanercept: in ankylosing spondylitis.

McCormack PL, Wellington K.

BioDrugs. 2004;18(3):199-205; discussion 206. Review.

PMID:
15161337
6.

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

Braun J, McHugh N, Singh A, Wajdula JS, Sato R.

Rheumatology (Oxford). 2007 Jun;46(6):999-1004. Epub 2007 Mar 27.

PMID:
17389658
7.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.

Ann Rheum Dis. 2004 Dec;63(12):1594-600. Epub 2004 Sep 2.

8.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2005 Mar;44(3):342-8. Epub 2004 Nov 23. Erratum in: Rheumatology (Oxford). 2005 Apr;44(4):569.

PMID:
15561737
9.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators.

Ann Rheum Dis. 2006 Dec;65(12):1572-7. Epub 2006 Sep 12.

10.

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.

Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.

Ann Rheum Dis. 2005 Nov;64(11):1557-62. Epub 2005 Apr 20.

11.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.

N Engl J Med. 1999 Jan 28;340(4):253-9.

12.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

13.

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.

Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I.

Ann Rheum Dis. 2010 Aug;69(8):1430-5. doi: 10.1136/ard.2009.121533. Epub 2010 May 28.

PMID:
20511606
14.

Etanercept in adult patients with early onset ankylosing spondylitis.

Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.

J Rheumatol. 2006 Aug;33(8):1634-6.

PMID:
16881118
15.

[Clinical study of etanercept for treating ankylosing spondylitis].

Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51. Chinese.

17.

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.

Ann Rheum Dis. 2008 Mar;67(3):346-52. Epub 2007 Oct 29.

18.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME.

Ann Intern Med. 1999 Mar 16;130(6):478-86.

PMID:
10075615
20.

Anti-TNF-alpha therapy for ankylosing spondylitis.

Son JH, Cha SW.

Clin Orthop Surg. 2010 Mar;2(1):28-33. doi: 10.4055/cios.2010.2.1.28. Epub 2010 Feb 4.

Supplemental Content

Support Center